Recalcitrant respiratory tract infections caused by bacteria have emerged as one of the
greatest health challenges worldwide. Aerosolized antimicrobial therapy is becoming …

The lungs are an attractive route for non-invasive drug delivery with advantages for both
systemic and local applications. Incorporating therapeutics with polymeric nanoparticles …

The lack of effective treatments for pulmonary diseases presents a significant global health
burden, primarily due to the challenges posed by the pulmonary barrier that hinders drug …

The 21st century has seen a paradigm shift to inhaled therapy, for both systemic and local
drug delivery, due to the lung's favourable properties of a large surface area and high …

Respiratory diseases are an increasing burden for the ageing population. Although our
understanding of these diseases has improved significantly over the past decades …

As the WHO stated, lower respiratory infections are the third leading cause of death. In
addition, it is remarkable that antimicrobial resistance represents a huge threat. Thus, new …

The pulmonary route has recently gained momentum as a suitable avenue for drug delivery.
The large alveolar surface area of approximately 75 m2 coupled with the thin epithelial …

Pulmonary diseases pose an immense threat to global health. Several nanotherapeutics-
based approaches aimed to tackle pulmonary ailments in recent years. The current …

Serious lung infections, such as pneumonia, tuberculosis, and chronic obstructive cystic
fibrosis‐related bacterial diseases, are increasingly difficult to treat and can be life …

The advent of nanotechnology has reignited interest in the lungs as a major route of drug
delivery for both systemic and local treatments. The large surface area of the lungs and the …